Another possibility is that testosterone levels get low to “the castration level” by LHRH agonists but may not get low enough against castration-refractory prostate cancer, as an upregulation of androgen receptor in prostate cancer, and changes in the signal transduction pathways downstream of the receptor get to utilize even little amount of testosterone. Here, AR is linked to prostate carcinoma.